Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
Recent Research Progress
Cyclin D1 (encoded by the CCND1 gene) is a G1 cyclin that is important for regulating the transition of G1 to S (G1-S) in different cell types. By cooperating with its binding partners CDK4 and CDK6, CCND1 promotes phosphorylation of retinoblastoma proteins, resulting in activation of the E2F transcription factor; thus, the cell cycle is passed through G1 into the S phase. Overexpression of CCND1 is commonly observed in various types of human cancers, including HCC, and serves a critical role in the initiation of carcinogenesis. CCND1 is also involved in abnormal cell growth processes, angiogenesis and resistance to apoptosis, making it a potential therapeutic target for tumor growth.
CCND1 and T-cell lymphoma
Adult T-cell lymphoma is a highly invasive T-cell malignancy. The study found that CCND1 levels were significantly elevated compared to adjacent non-tumor tissues, and miR-373 levels were significantly reduced in T-cell lymphoma tissues. Moreover, low miR-373 levels were associated with poor patient survival. Overexpression of miR-373 significantly inhibited cell growth, while consumption of miR-373 increased cell growth in T cell lymphoma cells. Furthermore, the effect of miR-373 on cell growth appeared to be caused by changes in cell proliferation. Finally, miR-373 was found to bind to the 3'-UTR of CCND1 mRNA to inhibit its translation in T cell lymphoma cells. In conclusion, a decrease in miR-373 levels in T-cell lymphoma tissue may contribute to the growth of T-cell lymphoma by CCND1-mediated cell proliferation.
CCND1 and CRC
Colorectal cancer (CRC) is one of the most common malignant gastrointestinal cancers, and its morbidity and mortality are on the rise. MicroRNA-374a (miR-374a) exhibits carcinogenic function in various tumor types. MiR-374a acts as a tumor suppressor by inactivating PI3K/AKT signaling and downstream signaling. This negative regulation was achieved by directly reducing CCND1 to inhibit proliferation, invasion and migration in colon cancer cells (Fig. 1). Furthermore, high miR-374a and low CCND1 expression in patient samples correlated with favorable outcomes, suggesting that miR-374a and CCND1 may be useful prognostic biomarkers.

Figure 1. Potential signaling pathway utilized by miR-374a to suppress proliferation, invasion and migration in colon cancer. (Qin AC, et al, Biochemical and Biophysical Research Communications, 2015)
CCND1 and OS
Metastasis is the leading cause of death in patients with osteosarcoma (OS). Overexpression of miR-195 has been reported to substantially inhibit the migration and invasion of OS cells in vitro and the formation of lung metastases in vivo. At the same time, CCND1 was identified as a target gene of miR-195 and further studied. Studies have indicated that low expression of miR-195 or high CCND1 was associated with positive overall survival and their expression inverse relate to each other. In conclusion, miR195 acts by down-regulating CCND1 as a tumor metastasis suppressor gene and can be used as a potential target for the treatment of OS.
CCND1 and HCC
The long non-coding RNA, homeobox transcript antisense RNA (Hotair), has been shown to play an important role in the regulation of various biological processes in hepatocellular carcinoma (HCC). Knockdown of HOTAIR expression by RNA interference inhibited cell proliferation and induces G0/G1 cell cycle arrest in Huh7 hepatocyte cancer cells. In addition, the expression levels of CCND1 mRNA and its CCND1 protein product were decreased in Huh7 cells after HOTAIR knockdown. Knockdown of HOTAIR reduced expression of phosphorylation signal transducer and activator of transcription 3 (STAT3), and binding of HOTAIR knockdown to STAT3 inhibition resulted in an additional decrease in CCND1 expression. The present studies have shown that Hotair may play a key role in the proliferation of liver cancer by regulating cell cycle, STAT3 activity and CCND1 expression. Therefore, Hotair may be a new potential therapeutic target for HCC therapy.
In conclusion, amplification and overexpression of CCND1 is frequently observed in a variety of tumors, which alters cell cycle progression. Therefore, further study of the mechanism of CCND1 in various cancers will provide new insights and new targets for the diagnosis and treatment of cancer.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.